每经头条（nbdtoutiao）——重磅解读！中国将不寻求WTO新的特殊和差别待遇，意味着什么？ （记者 王晓波） 每经AI快讯，金迪克9月30日晚间发布公告称，江苏金迪克生物技术股份有限公司董事会于近日收到公 司副总经理宋斌先生提交的辞职报告，宋斌先生因个人原因申请辞去副总经理职务，辞职后不再担任公 司任何职务。 ...

江苏金迪克生物技术股份有限公司 关于高级管理人员辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688670 证券简称：金迪克 公告编号：2025-025 | 姓名 | 离任职务 | 离任时间 | | 原定任期到 | | | 离任 | 是否继续在 上市公司及 | 具体职 务（如适 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 期日 | | | 原因 | 其控股子公 | 用） | 毕的公开 | | | | | | | | | | 司任职 | | 承诺 | | 宋斌 | 副总经理 | 2025 | 年 9 月 | 2026 年 | 5 | 月 | 个人 | 否 | 不适用 | 否 | | | | 30 | 日 | 10 | 日 | | 原因 | | | | 二、高级管理人员离任对公司的影响 宋斌先生已做好工作交接，其辞职不会对公司的生产经营造成不利影响。截 ...

Core Viewpoint - The resignation of Song Bin, the Deputy General Manager of Jiangsu Jindike Biotechnology Co., Ltd., is due to personal reasons and will not adversely affect the company's operations [1] Summary by Relevant Sections - **Resignation Details** - Song Bin submitted his resignation report and will no longer hold any position in the company after his departure on September 30, 2025, despite his term being originally set to end on May 10, 2026 [1] - He has completed the necessary work handover [1] - **Impact on Company Operations** - The company asserts that Song Bin's resignation will not negatively impact its production and operations [1] - **Stock and Commitments** - As of the announcement date, Song Bin does not hold any company stock and has no outstanding commitments [1]

Group 1 - The core point of the news is the decline in the stock price of Jindike Biotech, which fell by 5.05% to 14.66 CNY per share, with a total market capitalization of 1.806 billion CNY [1] - Jindike Biotech, established on December 29, 2008, focuses on the research, production, and sales of human vaccines, with 100% of its revenue derived from vaccine products [1] - The trading volume for Jindike Biotech was 6.309 million CNY, with a turnover rate of 0.34% [1] Group 2 - The Qianhai Kaiyuan Fund holds a significant position in Jindike Biotech, with 13,700 shares representing 1.11% of the fund's net value, making it the fifth-largest holding [2] - The fund, named Qianhai Kaiyuan Strong Consensus 100 Strong Stocks (001849), has a total scale of 17.2629 million CNY and has achieved a year-to-date return of 10.03% [2] - Over the past year, the fund has recorded a return of 30.13%, ranking 3212 out of 3814 in its category [2] Group 3 - The fund manager of Qianhai Kaiyuan Strong Consensus 100 Strong Stocks is Yuan Yichun, who has been in the position for 3 years and 38 days [3] - The total asset size of the fund is 67.572 million CNY, with the best return during Yuan's tenure being -9.11% and the worst being -26.57% [3]

Core Insights - The company JinDike (688670.SH) reported a revenue of 3.524 million yuan for the first half of 2025, representing a year-on-year increase of 7.18% [1][2] - The net profit attributable to the parent company was -39.653 million yuan, with a net profit excluding non-recurring items of -42.941 million yuan [1][2] - The net cash flow from operating activities was -85.488 million yuan [1][2] Financial Performance - For the first half of 2025, the company achieved a revenue of 3,524,238.84 yuan, up from 3,288,169.37 yuan in the same period last year, marking a 7.18% increase [2] - The net profit attributable to shareholders was -39,653,098.13 yuan, slightly improved from -40,867,089.23 yuan year-on-year [2] - The net profit after excluding non-recurring items was -42,940,823.45 yuan, compared to -47,145,812.18 yuan in the previous year [2] - The net cash flow from operating activities was -85,488,113.52 yuan, an improvement from -89,270,106.59 yuan in the same period last year [2] Yearly Comparison - In 2024, the company reported a revenue of 80.802 million yuan, a significant decrease of 39.96% compared to 134.591 million yuan in 2023 [3] - The net profit attributable to shareholders for 2024 was -93.502 million yuan, worsening from -70.990 million yuan in 2023 [3] - The net profit excluding non-recurring items was -106.224 million yuan, compared to -72.571 million yuan in the previous year [3] IPO and Fundraising - JinDike raised a total of 1.214 billion yuan from its initial public offering, with a net amount of 1.136 billion yuan, which was 464 million yuan less than initially planned [4] - The funds were intended for the construction of a new vaccine production facility, vaccine research and development, working capital, and repayment of bank loans [4] - The underwriting fees for the IPO totaled 78.2839 million yuan, with CITIC Securities receiving 64.3399 million yuan [4]

Group 1 - The Chinese government will include the HPV vaccine in the national immunization program, aiming to protect women's health and potentially eliminate cervical cancer by 2050 [1] - The inclusion of the HPV vaccine is expected to provide significant cost-effectiveness in preventing cervical cancer among adolescent females [1] Group 2 - Reports indicate that the Trump administration may consider an executive order to impose stricter restrictions on experimental drugs and clinical data from China, which has led to a decline in the stock prices of innovative drug companies in A-shares and H-shares [2] - However, some institutions believe that these restrictions may be mere posturing, as the development of Chinese innovative drugs continues to accelerate, with improvements in pipeline quantity and quality [2] Group 3 - Wang Chen has been removed from his position as Vice President of the Chinese Academy of Engineering, with the reasons for his dismissal remaining unclear [3] - Wang Chen is a prominent expert in respiratory medicine and has been involved in significant medical projects, which have previously sparked controversy [3] Group 4 - Zhang Jianhui, the General Manager of Jindike, passed away due to illness, marking a significant loss for the company and highlighting the risks associated with reliance on key individuals in the biotech sector [4] Group 5 - Qianhong Pharmaceutical received a regulatory letter due to its actual controller's failure to comply with disclosure obligations after increasing shareholding beyond the stipulated threshold [5] - The incident reflects potential internal control weaknesses within Qianhong Pharmaceutical [5]

Group 1 - The Chinese government will include the HPV vaccine in the national immunization program, aiming to protect women's health and potentially eliminate cervical cancer by 2050 [1] - The introduction of HPV vaccination for adolescent girls is expected to be cost-effective in preventing cervical cancer [1] Group 2 - Reports indicate that the Trump administration may consider an executive order to restrict experimental drugs and clinical data from China, which has led to a decline in the A-share and H-share innovative drug sectors [2] - Some institutions believe that the proposed restrictions may be mere posturing, as China's innovative drug development continues to progress significantly [2] - The potential executive order could create higher barriers for licensing agreements between Chinese pharmaceutical companies and large U.S. pharmaceutical firms if implemented [2] Group 3 - Wang Chen has been removed from his position as Vice President of the Chinese Academy of Engineering, though the reasons for this decision remain unclear [3] - Wang Chen is a prominent expert in respiratory medicine and has been involved in significant medical projects that have previously sparked controversy [3] Group 4 - Zhang Jianhui, the General Manager of Jindike, has passed away due to illness, marking a significant loss for the company and highlighting the risks associated with reliance on key individuals in the biotech sector [4] Group 5 - Qianhong Pharmaceutical received a regulatory letter due to its actual controller's failure to comply with disclosure obligations after increasing shareholding through block trading [5] - The increase in shareholding from 24.91% to 25.66% by the actual controller's concerted action partner indicates potential internal control issues within the company [5]

Core Viewpoint - The passing of Zhang Jianhui, the general manager of Jindike, is a significant event for the company, as he played a crucial role in its development and management [1][3]. Group 1: Company Leadership and Contributions - Zhang Jianhui was a major shareholder of Jindike since 2015 and was appointed as the general manager in October 2023 [3]. - He was recognized for his diligent work and significant contributions to the company's growth during his tenure [3]. - The board and employees expressed deep condolences and gratitude for his efforts [3]. Group 2: Shareholding and Financial Performance - As of the announcement date, Zhang held over 5.68 million shares, accounting for 4.61% of the total share capital, making him the third-largest shareholder [3][4]. - In the first half of 2025, Jindike reported a revenue of 3.5242 million yuan, a year-on-year increase of 7.18%, while the net profit attributable to shareholders was a loss of 39.6531 million yuan, a reduction in loss of 2.97% compared to the previous year [5]. Group 3: Company Operations and Market Position - Jindike's operations remain normal following Zhang's passing, with the board appointing Yu Jun to act as the general manager temporarily [4]. - As of September 10, 2023, Jindike's stock price was 15.96 yuan per share, with a total market capitalization of approximately 2 billion yuan [6].

Core Viewpoint - The company announced the passing of its General Manager, Zhang Jianhui, due to illness, highlighting his significant contributions to the company's development since 2015 [1] Company Overview - Zhang Jianhui served as a major shareholder of the company or its predecessor, Jiangsu Jindike Biotechnology Co., Ltd., since 2015 and was appointed General Manager in October 2023 [1] - He held 5.6804 million shares, representing 4.61% of the company's total share capital [1] - The company confirmed that its operations remain normal following Zhang's passing [1] Management Transition - The board of directors has appointed Chairman Yu Jun to act as the General Manager temporarily [1] - The company will expedite the process of appointing a new General Manager in accordance with the Company Law of the People's Republic of China and its articles of association [1]

Core Viewpoint - The company, Jindike (688670.SH), announced the unfortunate passing of its General Manager, Mr. Zhang Jianhui, due to illness at the age of 67 [1] Company Summary - Jindike has received notification from the family of Mr. Zhang Jianhui regarding his death [1]